Neuren Pharmaceuticals

Profil de la société

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Description disponible en anglais.

Informations sur la société

Secteur

Santé

Industrie

Biotechnology

Pays

Australie

Siège

117 Camberwell Road, 3123, Hawthorn East

Cotation

NEU · ASX

Indices

S&P/ASX 200

Devise

AUD

ISIN

NZNEUE0001S8

Site web

neurenpharma.com